KRAS G12C x Class I PI3K

剂量递增主要目的：评价HYP-2090PTSA在KRAS突变的晚期实体瘤患者中的安全性和耐受性；确定HYP-2090PTSA推荐II期剂量（RP2D）和/或最大耐受剂量（MTD）。剂量扩展主要目的：评价HYP-2090PTSA在KRAS G12C突变的晚期实体瘤患者中的有效性。

This is a multicenter, open-label phase 1/2 study consisting of two parts: dose escalation phase and dose expansion phase. The objective of the dose escalation phase is to evaluate the safety, tolerability and pharmacokinetics of HYP-2090PTSA in patients with advanced solid tumors harboring KRAS mutation and to determine the RP2D. In the dose expansion phase, preliminary efficacy and safety at the RP2D will be further explored in patients with specific cancer harboring KRAS p.G12C mutation.